Topical treatment of diabetic macular edema using dexamethasone ophthalmic suspension: A randomized, double‐masked, vehicle‐controlled study

To evaluate topical dexamethasone ophthalmic suspension OCS‐01 (Oculis SA, Lausanne, Switzerland) in diabetic macular edema (DME).

[1]  E. Stefánsson,et al.  Aqueous eye drops containing drug/cyclodextrin nanoparticles deliver therapeutic drug concentrations to both anterior and posterior segment , 2021, Acta ophthalmologica.

[2]  D. Angoulvant,et al.  Cardiovascular Adverse Events With Intravitreal Anti-Vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Clinical Trials. , 2021, JAMA ophthalmology.

[3]  David F Williams,et al.  Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes , 2020, British Journal of Ophthalmology.

[4]  T. Hong,et al.  Burden Of Treatment Among Patients Undergoing Intravitreal Injections For Diabetic Macular Oedema In Australia , 2019, Diabetes, metabolic syndrome and obesity : targets and therapy.

[5]  Jennifer K. Sun,et al.  Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab: A Post Hoc Analysis of the Protocol T Randomized Clinical Trial. , 2019, JAMA ophthalmology.

[6]  Sonia M. Thomas,et al.  Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis , 2019, BMJ Open.

[7]  M. Urbančič,et al.  Dexamethasone implant in the management of diabetic macular edema from clinician’s perspective , 2019, Clinical ophthalmology.

[8]  E. Stefánsson,et al.  Topical drug delivery to the posterior segment of the eye: The effect of benzalkonium chloride on topical dexamethasone penetration into the eye in vivo , 2018, Journal of Drug Delivery Science and Technology.

[9]  D. Browning,et al.  Diabetic macular edema: Evidence-based management , 2018, Indian journal of ophthalmology.

[10]  A. Denniston,et al.  Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review , 2018, Ophthalmology and Therapy.

[11]  E. Stefánsson,et al.  Topical drug delivery to the posterior segment of the eye: Dexamethasone concentrations in various eye tissues after topical administration for up to 15 days to rabbits , 2018 .

[12]  S. Kiss,et al.  Vision Outcomes Following Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice. , 2018, American journal of ophthalmology.

[13]  N. Bressler,et al.  Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T , 2017, Current opinion in ophthalmology.

[14]  E. Stefánsson,et al.  Cyclodextrins and topical drug delivery to the anterior and posterior segments of the eye. , 2017, International journal of pharmaceutics.

[15]  Savleen Kaur,et al.  Steroid-induced Glaucoma: An Avoidable Irreversible Blindness , 2017, Journal of current glaucoma practice.

[16]  A. Urtti,et al.  Pharmacokinetic aspects of retinal drug delivery , 2017, Progress in Retinal and Eye Research.

[17]  A. Wenzel,et al.  Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials , 2016, Clinical ophthalmology.

[18]  Jennifer K. Sun,et al.  Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. , 2016, JAMA ophthalmology.

[19]  S. Sivaprasad,et al.  A randomized clinical trial comparing fixed vs pro-re-nata dosing of Ozurdex in refractory diabetic macular oedema (OZDRY study) , 2015, Eye.

[20]  E. Stefánsson,et al.  Topical dexamethasone γ‐cyclodextrin nanoparticle eye drops increase visual acuity and decrease macular thickness in diabetic macular oedema , 2015, Acta ophthalmologica.

[21]  E. Stefánsson,et al.  Topical dexamethasone–cyclodextrin nanoparticle eye drops for non‐infectious Uveitic macular oedema and vitritis – a pilot study , 2015, Acta ophthalmologica.

[22]  A. Hessellund,et al.  Topical dexamethasone–cyclodextrin microparticle eye drops for uveitic macular oedema , 2014, Acta ophthalmologica.

[23]  P. Kaiser,et al.  Intravitreal aflibercept for diabetic macular edema. , 2014, Ophthalmology.

[24]  Takuhiro Yamaguchi,et al.  Systemic vascular safety of ranibizumab for age-related macular degeneration: systematic review and meta-analysis of randomized trials. , 2014, Ophthalmology.

[25]  S. Whitcup,et al.  Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. , 2014, Ophthalmology.

[26]  Quan Dong Nguyen,et al.  Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. , 2012, Ophthalmology.

[27]  E. Stefánsson,et al.  Topical dexamethasone-cyclodextrin microparticle eye drops for diabetic macular edema. , 2011, Investigative ophthalmology & visual science.

[28]  P. Campochiaro,et al.  Topical mecamylamine for diabetic macular edema. , 2010, American journal of ophthalmology.

[29]  H. Yamashita,et al.  Steroid eye drop treatment (difluprednate ophthalmic emulsion) is effective in reducing refractory diabetic macular edema , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.

[30]  E. Stefánsson,et al.  Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops , 2007, The Journal of pharmacy and pharmacology.

[31]  S. Parapuram,et al.  Corticosteroids and Glaucoma Risk , 1999, Drugs & aging.

[32]  R. Avery,et al.  Systemic Safety of Prolonged Monthly Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema: A Systematic Review and Meta-analysis. , 2016, JAMA ophthalmology.